Medpace Holdings, Inc. (FRA:01P)
Germany · Delayed Price · Currency is EUR | Market Cap | 16.72B +26.0% |
| Revenue (ttm) | 2.50B +20.4% |
| Net Income | 456.00M +19.6% |
| EPS | 16.10 +25.9% |
| Shares Out | n/a |
| PE Ratio | 36.92 |
| Forward PE | 34.36 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 571.00 |
| Previous Close | 574.00 |
| Day's Range | 570.40 - 594.20 |
| 52-Week Range | 330.40 - 597.60 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 21, 2026 |
About Medpace Holdings
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data man... [Read more]
Financial Performance
In 2025, Medpace Holdings's revenue was $2.53 billion, an increase of 19.97% compared to the previous year's $2.11 billion. Earnings were $451.12 million, an increase of 11.57%.
Financial numbers in USD Financial StatementsNews
Medpace price target raised to $633 from $609 at Truist
Truist analyst Jailendra Singh raised the firm’s price target on Medpace (MEDP) to $633 from $609 and keeps a Hold rating on the shares after its Q3 earnings beat. The…
Medpace price target raised to $700 from $673 at UBS
UBS raised the firm’s price target on Medpace (MEDP) to $700 from $673 and keeps a Neutral rating on the shares.
Medpace price target raised to $673 from $492 at TD Cowen
TD Cowen raised the firm’s price target on Medpace (MEDP) to $673 from $492 and keeps a Hold rating on the shares. The firm said its earnings call commentary included…
Medpace price target raised to $730 from $700 at Mizuho
Mizuho raised the firm’s price target on Medpace (MEDP) to $730 from $700 and keeps an Outperform rating on the shares. The firm cites an improved book-to-bill following the Q3…
Medpace price target raised to $699 from $638 at Baird
Baird raised the firm’s price target on Medpace (MEDP) to $699 from $638 and keeps an Outperform rating on the shares. The firm updated its model following Q3 results. Published…
Medpace price target raised to $675 from $625 at Barclays
Barclays raised the firm’s price target on Medpace (MEDP) to $675 from $625 and keeps an Equal Weight rating on the shares.
Medpace Holdings Earnings Call Transcript: Q3 2026
Q3 revenue rose 8.5% YoY, EBITDA margin reached 24%, and awards set a quarterly record. FY2026 guidance increased, while 2027 expectations remain sensitive to Q4 awards and cancellations.
Medpace Holdings Earnings release: Q3 2026
Medpace Holdings released its Q3 2026 earnings on October 22, 2026, summarizing the period's financial results.
Medpace Holdings Slides: Q3 2026
Medpace Holdings has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on October 22, 2026.
Medpace Holdings Quarterly report: Q3 2026
Medpace Holdings has published its Q3 2026 quarterly earnings report on October 22, 2026.
Medpace Holdings, Inc. Reports Third Quarter 2026 Results
CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced financial results for the third quarter ended September 30, 2026. Third Quarter 2026 Financial Results Re...
Medpace price target raised to $700 from $665 at Mizuho
Mizuho raised the firm’s price target on Medpace (MEDP) to $700 from $665 and keeps an Outperform rating on the shares. The firm adjusted targets in the healthcare facilities and…
Medpace price target raised to $625 from $600 at Barclays
Barclays raised the firm’s price target on Medpace (MEDP) to $625 from $600 and keeps an Equal Weight rating on the shares. The firm adjusted targets in the life science…
Medpace resumed with a Neutral at UBS
UBS resumed coverage of Medpace (MEDP) with a Neutral rating and $673 price target UBS assumed coverage of the contract research organization industry with a constructive view on fundamentals, citing…
Medpace Holdings, Inc. to Report Third Quarter 2026 Financial Results on October 21, 2026
CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced that it will report its third quarter 2026 financial results after the market close on Wednesday, October...
Medpace price target raised to $692 from $484 at RBC Capital
RBC Capital analyst Ryan Halsted raised the firm’s price target on Medpace (MEDP) to $692 from $484 and keeps an Outperform rating on the shares. The company’s Q2 results represent…
Medpace price target raised to $665 from $586 at Mizuho
Mizuho raised the firm’s price target on Medpace (MEDP) to $665 from $586 and keeps an Outperform rating on the shares. The firm sees improving bookings visibility post the company’s…
Medpace price target raised to $600 from $400 at BMO Capital
BMO Capital raised the firm’s price target on Medpace (MEDP) to $600 from $400 and keeps a Market Perform rating on the shares. The revenue mix continues to shift from…
Medpace price target raised to $492 from $419 at TD Cowen
TD Cowen analyst Charles Rhyee raised the firm’s price target on Medpace (MEDP) to $492 from $419 and keeps a Hold rating on the shares. The firm thinks the company’s…
Medpace price target raised to $624 from $547 at Baird
Baird raised the firm’s price target on Medpace (MEDP) to $624 from $547 and keeps a Neutral rating on the shares.
Medpace price target raised to $620 from $515 at Leerink
Leerink raised the firm’s price target on Medpace (MEDP) to $620 from $515 and keeps a Market Perform rating on the shares.
Medpace price target raised to $600 from $450 at Barclays
Barclays analyst Luke Sergott raised the firm’s price target on Medpace (MEDP) to $600 from $450 and keeps an Equal Weight rating on the shares. The firm updated the company’s…
Medpace Holdings Earnings Call Transcript: Q2 2026
Q2 2026 delivered strong revenue and net income growth, with record net bookings and a robust business environment. Oncology bookings surged, cancellations declined, and guidance for 2026 was raised, projecting double-digit growth in revenue and EBITDA.